Zenas BioPharma develops immune system drugs for autoimmune diseases, led by the antibody candidate obexelimab. ZBIO reports earnings on Wed, Nov 18, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 30 | Citigroup | Maintained | Buy | |
| Aug 14 | Morgan Stanley | Maintained | Hold | |
| Aug 14 | Wedbush | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in ZBIO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZBIO is in one of them and how their past ZBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZBIO in an article yet. Here's the latest on the wider market.
About Zenas BioPharma
Zenas BioPharma is a biopharmaceutical company based in Waltham, Massachusetts, that develops drugs targeting the immune system to treat autoimmune diseases. Its lead candidate, obexelimab, is an antibody designed to calm B cells, which play a role in conditions such as IgG4-related disease, relapsing multiple sclerosis and lupus. The company is also developing orelabrutinib, an oral drug for progressive forms of multiple sclerosis, along with several earlier stage candidates. It has no approved products and does not sell drugs today, so its intended customers are patients with autoimmune diseases and the doctors who treat them.
- Headquarters
- Waltham, MA